Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections

Journal of Microbiology, Immunology and Infection

Volumn 35, Issue 3, 2002, Pages 159-167

  Huang, Chun Kai ^a   Chen, Yao Shen ^a   Lee, Susan Shin Jung ^a   Lin, Wei Ru ^a   Tsai, Hung Chin ^a   Lin, Hsi Hsun ^a   Wann, Shue Ren ^a   Chen, Joanna Yan Wan ^a   Yen, Muh Yong ^a   Liu, Yung Ching ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cefepime; Ceftazidime; Severe bacterial infections

Indexed keywords

CEFEPIME; CEFTAZIDIME;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARANEOPLASTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; SALMONELLA PARATYPHI; SEPTICEMIA; SUPERINFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADOLESCENT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEFTAZIDIME; CEPHALOSPORINS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TAIWAN; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 0036744158     PISSN: 02532662     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Eron LJ, Goldenberg RI, Park CH, Poretz DM. Ceftazidime therapy of serious bacterial infections. Antimicrob Agents Chemother 1983;23:236-41.
2. Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikalis P. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative bacterial infections. Antimicrob Agents Chemother 1989;33:1362-7.
3. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Eng J Med 1986;315:552-8.
4. Wang FD, Liu CY, Hsu HC, Gau JP, Chau WK, Haung ML, Ho CH. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999;45:370-9.
5. Oster S, Edlstein H, Cassano K, McCabe R. Open trial of cefepime (BMY 28142) for infections in hospitalized patients. Antimicrob Agents Chemother 1990;34:954-7.
6. Sheng WH, Wang JT, Chang SC. Efficacy and safety of cefepime in the treatment of serious bacterial infections in hospitalized adult patients. J Microbiol Immunol Infect 2000; 33:109-14.
7. Kalman D, Barriere SL, Johnson BL. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother 1992;36:453-7.
8. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994;47:471-505.
9. Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA. Cefepime: a new fourth generation cephalosporin. Am J Hosp Pharm 1994;51:463-77.
10. Cunha BA, Gill MV. Cefepime. Med Clin North Am 1995;79: 721-32.
11. Fekete T, Tumah H, Woodwell J, Satishchandran V, Truant A, Axelrod P. Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary-care university hospital. Am J Med 1996;100:S20-5.
12. Thornsberry C, Yee YC. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J Med 1996;100: S26-38.
13. Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 1985;27:679-82.
14. Jacoby GA, Sutton L. β-Lactamases and β-lactam resistance in Escherichia coli. Antimicrob Agents Chemother 1985;27: 703-5.
15. Neu HC, Chin NX, Jules K, Labthavikul P. The activity of BMY 28142 a new broad spectrum β-lactamase stable cephalosporin. J Antimicrob Chemother 1986; 17:441-52.
16. Phelps DJ, Carlton DD, Farrell CA, Kessler RE. Affinity of cephalosporins for β-lactamases as a factor in antimicrobial efficacy. Antimicrob Agents Chemother 1986;29:845-8.
17. Kessler RE, Bies M, Buck RE, Chisholm DR, Pursiano TA, Tsai YH, Misiek M, Price KE, Leitner F. Comparison of a new cephalosporin, BMY-28142, with other broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother 1985;27:207-16.
18. Ramphal R, Gucalp R, Rotstein C, Cimino M, Odlon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996;100(Suppl):S83-9.
19. Lister PD, Sanders WE Jr, Sanders CC. Cefepime-aztreonam: a double β-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42:1610-9.
20. Gentry LO, Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Amimicrob Agents Chemother 1991;35:2371-4.
21. Chang SC, Fang CT, Hsueh PR, Liu CJ, Sheng WH, Hsieh SM, Hung CC, Chen YC. Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment. Int J Antimicrob Agents 1998;10:245-8.
22. Wang FD, Liu IM, Liu CY. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria. Chinese Med J (Taipei) 1998;61:408-13.
23. Lin JC, Yeh KM, Peng MY, Chang FY. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia. J Microbial Immunol Infect 2001;34:131-7.
24. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA, and the Methylprednisolone Severe Sepsis Study Group. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989;17:389-93.
25. Naito T, Aburaki S, Kamachi H, Narita Y, Okumara J, Kawaguchi H. Synthesis and structure activity relationship of a new series of cephalosporins, BMY 28142 and related compounds. J Antibiotics 1986;39:1092-107.
26. Wanatable N, Hiruma R, Katsu K. Comparative in vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime-resistant or imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1992;30: 633-41.
27. Tsuji A, Maniatis A, Bertram MA. Young LS. In vitro activity of BMY-28142 in comparison with those of other β-lactam antimicrobial agents. Antimicrob Agents Chemother 1985;27: 515-9.
28. Vuye A, Pijck J. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrob Agents Chemother 1985;27:574-7.
29. Liu YC, Huang WK, Cheng DL. Antibacterial activity of cefepime in vitro. Chemotherapy 1994;40:384-90.
30. Leophonte P, Bertrand A, Nouvet G, Muir JF, Lucht F, Delaval P, Depierre A, Hughes F, Ulmer M, Gres JJ. A comparative study of cefepime vs ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 1993;31:S165-73.
31. Kieft H, Hoepelman AIM, Rozenberg-Arska M, Branger JM, Voskuil JH, Geers AB, Kluyver M, Hart HC, Poest-Clement E, van Beugen L. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother 1994;38:415-21.
32. Hoepelman AIM, Kieft H, Aoun M, Kosmidis J, Strand T, Verhoef J, Gillespie SH, Riddell J, Varghese G, Meunier F. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother 1993;32:S175-86.
33. Schrank JH Jr, Kelly JW, McAllister CK. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis 1995;20:56-8.
34. Giamarellou H. Low-dose cefepime in the treatment of serious bacterial infections. J Antimicrob Chemother 1993;32:S123-32.
35. Schrank JH Jr, Kelly JW, McAllister CK. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis 1995;20:56-8.
36. Guerra JG, Casalino E, Palomino JC, Barboza E, Castillo M, Gonzalez del Riego M, Huapaya V, Antunez de Mayolo E. Imipenem/cilastatin vs gentamicin/clindamycin for the treatment of moderate to severe infections in hospitalized patients. Rev Infect Dis 1985;7(Suppl):S463-70.
37. Hoepelman AIM, Rozenberg-Arska M, Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet 1988;1:1305-9.
38. Smith CR, Ambinder R, Lipsky JJ, Petty BG, Israel E, Levitt R, Mellits ED, Rocco L, Longstreth J, Lietman PS. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infection. Ann Intern Med 1984;101:469-77.
39. Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteremia and outcome from sepsis. QJ Med 1996;89:515-22.
40. Centers for Disease Control. Nosocomial infection surveillance, 1980-82. In: CDC surveillance summaries. MMWR 1983;22: 155.
41. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 1996;100(Suppl):S68-75.